Last update 23 Jan 2025
Genmedicn Biopharma Inc.

Genmedicn Biopharma Inc.

Private Company|
2020|
Jiangsu Sheng, China

Overview

Tags

Hemic and Lymphatic Diseases
Congenital Disorders
Endocrinology and Metabolic Disease
Gene therapy
AAV based gene therapy
Stem cell therapy

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Hemic and Lymphatic Diseases3
Endocrinology and Metabolic Disease1
Infectious Diseases1
Top 5 Drug TypeCount
Gene therapy2
AAV based gene therapy2
Stem cell therapy1
Top 5 TargetCount
COL7A1(Collagen alpha-1(VII) chain)1
EXOSC3(exosome component 3)1

Related

5
Drugs associated with Genmedicn Biopharma Inc.
GMCN-508B
Target-
Mechanism
Cell replacements
Active Org.
First Affiliated Hospital of Guangxi Medical UniversityFirst Affiliated Hospital of Guangxi Medical University [+1]
Originator Org.
Genmedicn Biopharma Inc.Genmedicn Biopharma Inc.
Active Indication
Transfusion-dependent Beta Thalassemia [+1]
Inactive Indication-
Drug Highest PhaseEarly Phase 1
First Approval Ctry. / Loc.-
First Approval Date-
GMCN-626
Target-
Mechanism-
Active Org.
Genmedicn Biopharma Inc.Genmedicn Biopharma Inc.
Originator Org.
Genmedicn Biopharma Inc.Genmedicn Biopharma Inc.
Active Indication
Pyruvate Kinase Deficiency
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
CN116555349
Patent Mining
Target
COL7A1
Mechanism-
Active Org.
Genmedicn Biopharma Inc.Genmedicn Biopharma Inc.
Originator Org.
Genmedicn Biopharma Inc.Genmedicn Biopharma Inc.
Active Indication
Skin Diseases, Genetic
Inactive Indication-
Drug Highest PhaseDiscovery
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Genmedicn Biopharma Inc.
NCT05762510
/ RecruitingEarly Phase 1IIT
An Open Label Study Evaluating the Safety and Efficacy of Gene Therapy for Transfusion-dependent β-Thalassemia by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a LentiRed Lentiviral Vector (GMCN-508B Drug Product, Also Called LentiRed)
100 Clinical Results associated with Genmedicn Biopharma Inc.
Login to view more data
0 Patents (Medical) associated with Genmedicn Biopharma Inc.
Login to view more data
100 Deals associated with Genmedicn Biopharma Inc.
Login to view more data
100 Translational Medicine associated with Genmedicn Biopharma Inc.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
3
1
Preclinical
Phase 1 Clinical
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
GMCN-508B
Transfusion-dependent Beta Thalassemia
More
Phase 1 Clinical
GMCN-626
Pyruvate Kinase Deficiency
More
Preclinical
CN116555349
 ( COL7A1 )		Skin Diseases, Genetic
More
Discovery
GMCN-6250
Anemia
More
Discovery
WO2022166027
 ( EXOSC3 )		Infectious Diseases
More
Discovery
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free